-
1
-
-
0035945656
-
Estrogen and the risk of breast cancer
-
Erratum, N Engl J Med 2001;344:1804
-
Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85. [Erratum, N Engl J Med 2001;344:1804.]
-
(2001)
N Engl J Med
, vol.344
, pp. 276-285
-
-
Clemons, M.1
Goss, P.2
-
2
-
-
54049117698
-
Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women
-
Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
-
(2008)
Cancer Epidemiol Biomarkers Prev
, vol.17
, pp. 2029-2035
-
-
Eliassen, A.H.1
Missmer, S.A.2
Tworoger, S.S.3
Hankinson, S.E.4
-
3
-
-
5344222810
-
Growth patterns and the risk of breast cancer in women
-
DOI 10.1056/NEJMoa040576
-
Ahlgren M, Melbye M, Wohlfahrt J, Sørensen TIA. Growth patterns and the risk of breast cancer in women. N Engl J Med 2004;351:1619-26. (Pubitemid 39350422)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.16
, pp. 1619-1626
-
-
Ahlgren, M.1
Melbye, M.2
Wohlfahrt, J.3
Sorensen, T.I.A.4
-
4
-
-
0037123341
-
Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies
-
The Endogenous Hormones and Breast Cancer Collaborative Group
-
The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 606-616
-
-
-
5
-
-
0032537990
-
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
-
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
-
(1998)
Journal of the National Cancer Institute
, vol.90
, Issue.18
, pp. 1371-1388
-
-
Fisher, B.1
Costantino, J.P.2
Wickerham, D.L.3
Redmond, C.K.4
Kavanah, M.5
Cronin, W.M.6
Vogel, V.7
Robidoux, A.8
Dimitrov, N.9
Atkins, J.10
Daly, M.11
Wieand, S.12
Tan-Chiu, E.13
Ford, L.14
Wolmark, N.15
-
6
-
-
0037464769
-
Overview of the main outcomes in breast-cancer prevention trials
-
DOI 10.1016/S0140-6736(03)12342-2
-
Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300. (Pubitemid 36126189)
-
(2003)
Lancet
, vol.361
, Issue.9354
, pp. 296-300
-
-
Cuzick, J.1
Powles, T.2
Veronesi, U.3
Forbes, J.4
Edwards, R.5
Ashley, S.6
Boyle, P.7
-
7
-
-
77953517123
-
Long-term follow-up in cancer prevention trials (It ain't over till it's over)
-
Phila
-
Cuzick J. Long-term follow-up in cancer prevention trials (It ain't over till it's over). Cancer Prev Res (Phila) 2010;3:689-91.
-
(2010)
Cancer Prev Res
, vol.3
, pp. 689-691
-
-
Cuzick, J.1
-
8
-
-
33745876266
-
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
-
DOI 10.1056/NEJMoa062462
-
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37. (Pubitemid 44050394)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.2
, pp. 125-137
-
-
Barrett-Connor, E.1
Mosca, L.2
Collins, P.3
Geiger, M.J.4
Grady, D.5
Kornitzer, M.6
McNabb, M.A.7
Wenger, N.K.8
-
9
-
-
10644283864
-
Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
-
DOI 10.1093/jnci/djh319
-
Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61. (Pubitemid 39654569)
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.23
, pp. 1751-1761
-
-
Martino, S.1
Cauley, J.A.2
Barrett-Connor, E.3
Powles, T.J.4
Mershon, J.5
Disch, D.6
Secrest, R.J.7
Cummings, S.R.8
Mautalen, C.A.9
Zanchetta, J.R.10
Hooper, M.J.11
Ng, K.W.12
Prince, R.L.13
Nicholson, G.14
Roberts, A.P.15
Seeman, E.16
Williamson, M.17
Boschitsch, E.18
Leb, G.19
Body, J.J.20
Devogelaer, J.P.21
Geusens, P.22
Kaufman, J.-M.23
Peretz, A.24
Adachi, J.25
Bensen, W.26
Brown, J.P.27
Cheung, A.28
Chik, C.29
Gee, S.30
Hanley, D.31
Hawker, G.A.32
Hodsman, A.B.33
Joyce, C.34
Monchesky, T.C.35
Olszynski, W.P.36
Roe, B.37
Senikas, V.38
Seminoski, K.39
Wall, J.40
Stepan, J.41
Hyldstrup, L.42
Langdahl, B.43
Sorensen, T.H.44
Alhava, E.45
Kormano, M.46
Salmela, P.47
Salmi, J.48
Valimaki, M.49
Audran, M.50
Briancon, D.51
Delmas, P.52
Fardellone, P.53
Ribot, C.54
De Vernejoul, M.C.55
Balogh, A.56
Julesz, J.57
Szuecs, J.58
Karsik, A.59
Fiore, C.60
Genazzani, A.R.61
Gennari, C.62
Isaia, G.C.63
Melis, G.B.64
Nuti, R.65
Oriente, P.66
Passeri, M.67
Sartori, L.68
Corea-Rotter, R.69
Gonzalez, S.70
Murillo, A.71
Jonker, J.J.72
Lips, P.73
Mulder, H.74
Pols, H.A.75
Halse, J.I.76
Hoiseth, A.77
Jorde, R.78
Olford, E.S.79
Skag, A.80
Stakkestad, J.A.81
Wist, E.82
Badurski, J.E.83
Hoszowski, K.84
Ogonowski, J.85
Bose, K.86
Lee, K.O.87
Dzurik, R.88
Kocijancic, A.89
Cannata, A.J.B.90
Collado, R.C.91
Carranza, F.H.92
Diez-Perez, A.93
Escobar-Jimenez, F.94
Minguella, J.F.95
Solan, X.N.96
Torres, M.M.97
Larsson, K.98
Malstroem, D.99
more..
-
10
-
-
33745249570
-
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
-
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
-
(2006)
JAMA
, vol.295
, pp. 2727-2741
-
-
Vogel, V.G.1
Costantino, J.P.2
Wickerham, D.L.3
-
11
-
-
33750985352
-
Prescription of tamoxifen for breast cancer prevention by primary care physicians
-
DOI 10.1001/archinte.166.20.2260
-
Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006;166:2260-5. (Pubitemid 44748773)
-
(2006)
Archives of Internal Medicine
, vol.166
, Issue.20
, pp. 2260-2265
-
-
Armstrong, K.1
Quistberg, D.A.2
Micco, E.3
Domchek, S.4
Guerra, C.5
-
12
-
-
33750575970
-
The dilemma and promise of cancer chemoprevention
-
DOI 10.1038/ncponc0609, PII NCPONC0609
-
Lippman SM. The dilemma and promise of cancer chemoprevention. Nat Clin Pract Oncol 2006;3:523. (Pubitemid 44781718)
-
(2006)
Nature Clinical Practice Oncology
, vol.3
, Issue.10
, pp. 523
-
-
Lippman, S.M.1
-
13
-
-
77954573787
-
Patient decisions about breast cancer chemoprevention: A systematic review and meta-analysis
-
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-5.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3090-3095
-
-
Ropka, M.E.1
Keim, J.2
Philbrick, J.T.3
-
14
-
-
67650333853
-
American Society of Clinical Oncology 2008 clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
-
Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology 2008 clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3235-3258
-
-
Visvanathan, K.1
Chlebowski, R.T.2
Hurley, P.3
-
15
-
-
76149136014
-
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women
-
Waters WA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010;19:443-6.
-
(2010)
Cancer Epidemiol Biomarkers Prev
, vol.19
, pp. 443-446
-
-
Waters, W.A.1
Cronin, K.A.2
Graubard, B.I.3
Han, P.K.4
Freedman, A.N.5
-
16
-
-
0036682052
-
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
-
DOI 10.1200/JCO.2002.06.029
-
Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20:3328-43. (Pubitemid 34831530)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.15
, pp. 3328-3343
-
-
Chlebowski, R.T.1
Col, N.2
Winer, E.P.3
Collyar, D.E.4
Cummings, S.R.5
Vogel III, V.G.6
Burstein, H.J.7
Eisen, A.8
Lipkus, I.9
Pfister, D.G.10
-
17
-
-
79954594388
-
Personalized estimates of breast cancer risk in clinical practice and public health
-
Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 2011;30:1090-104.
-
(2011)
Stat Med
, vol.30
, pp. 1090-1104
-
-
Gail, M.H.1
-
18
-
-
0242541260
-
Breast cancer prevention - Clinical trials strategies involving aromatase inhibitors
-
DOI 10.1016/S0960-0760(03)00378-9
-
Goss PE. Breast cancer prevention - clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86:487-93. (Pubitemid 37412588)
-
(2003)
Journal of Steroid Biochemistry and Molecular Biology
, vol.86
, Issue.3-5
, pp. 487-493
-
-
Goss, P.E.1
-
19
-
-
0028594068
-
Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats
-
Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-80.
-
(1994)
Carcinogenesis
, vol.15
, pp. 2775-2780
-
-
Lubet, R.A.1
Steele, V.E.2
Casebolt, T.L.3
Eto, I.4
Kelloff, G.J.5
Grubbs, C.J.6
-
20
-
-
0026518230
-
Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors
-
De Coster R, Van Ginckel RF, Callens MJ, Goeminne NK, Janssens BL. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 1992;52:1240-4.
-
(1992)
Cancer Res
, vol.52
, pp. 1240-1244
-
-
De Coster, R.1
Van Ginckel, R.F.2
Callens, M.J.3
Goeminne, N.K.4
Janssens, B.L.5
-
21
-
-
0027230575
-
Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors
-
Schieweck K, Bhatnagar AS, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993;44:633-6. (Pubitemid 23126637)
-
(1993)
Journal of Steroid Biochemistry and Molecular Biology
, vol.44
, Issue.4-6
, pp. 633-636
-
-
Schieweck, K.1
Bhatnagar, A.S.2
Batzl, C.3
Lang, M.4
-
22
-
-
0142181118
-
Anastrozole Alone or in Combination with Tamoxifen versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early-Stage Breast Cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trial Efficacy and Safety Update Analyses
-
DOI 10.1002/cncr.11745
-
Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10. (Pubitemid 37310221)
-
(2003)
Cancer
, vol.98
, Issue.9
, pp. 1802-1810
-
-
Baum, M.1
Buzdar, A.2
Cuzick, J.3
Forbes, J.4
Houghton, J.5
Howell, A.6
Sahmoud, T.7
-
23
-
-
29544433211
-
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
The Breast International Group (BIG) 1-98 Collaborative Group. [Erratum, N Engl J Med 2006;354:2200.]
-
The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57. [Erratum, N Engl J Med 2006;354:2200.]
-
(2005)
N Engl J Med
, vol.353
, pp. 2747-2757
-
-
-
24
-
-
10744223655
-
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
-
Errata, 2004;351:2461, 2006;355:1746
-
Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. [Errata, 2004;351:2461, 2006;355:1746.]
-
(2004)
N Engl J Med
, vol.350
, pp. 1081-1092
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
-
25
-
-
78751647876
-
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomized phase 3 trial
-
van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet 2011;377:321-31.
-
(2011)
Lancet
, vol.377
, pp. 321-331
-
-
Van De Velde, C.J.1
Rea, D.2
Seynaeve, C.3
-
26
-
-
7444259675
-
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
-
DOI 10.1056/NEJMoa032312
-
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. (Pubitemid 37362955)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.19
, pp. 1793-1802
-
-
Goss, P.E.1
Ingle, J.N.2
Martino, S.3
Robert, N.J.4
Muss, H.B.5
Piccart, M.J.6
Castiglione, M.7
Tu, D.8
Shepherd, L.E.9
Pritchard, K.I.10
Livingston, R.B.11
Davidson, N.E.12
Norton, L.13
Perez, E.A.14
Abrams, J.S.15
Therasse, P.16
Palmer, M.J.17
Pater, J.L.18
-
27
-
-
75749092296
-
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
-
Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-18.
-
(2010)
J Clin Oncol
, vol.28
, pp. 509-518
-
-
Dowsett, M.1
Cuzick, J.2
Ingle, J.3
-
28
-
-
1542346356
-
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
-
DOI 10.1016/j.bone.2003.11.006, PII S8756328203004162
-
Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004;34:384-92. (Pubitemid 38314903)
-
(2004)
Bone
, vol.34
, Issue.3
, pp. 384-392
-
-
Goss, P.E.1
Qi, S.2
Josse, R.G.3
Pritzker, K.P.H.4
Mendes, M.5
Hu, H.6
Waldman, S.D.7
Grynpas, M.D.8
-
29
-
-
0030748661
-
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidai aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study
-
Joahannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-8. (Pubitemid 27319756)
-
(1997)
Clinical Cancer Research
, vol.3
, Issue.7
, pp. 1101-1108
-
-
Johannessen, D.C.1
Engan, T.2
Di, S.E.3
Zurlo, M.G.4
Paolini, J.5
Ornati, G.6
Piscitelli, G.7
Kvinnsland, S.8
Lonning, P.E.9
-
30
-
-
36549088561
-
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
-
Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007;9:R52.
-
(2007)
Breast Cancer Res
, vol.9
-
-
Goss, P.E.1
Hadji, P.2
Subar, M.3
Abreu, P.4
Thomsen, T.5
Banke-Bochita, J.6
-
31
-
-
79959428142
-
Minimization Procedure
-
Chow SC, ed. 3rd ed. New York: Marcel Dekker
-
Tu D. Minimization Procedure. In: Chow SC, ed. Encyclopedia of biopharmaceutical statistics. 3rd ed. New York: Marcel Dekker, 2010:795-8.
-
(2010)
Encyclopedia of Biopharmaceutical Statistics
, pp. 795-798
-
-
Tu, D.1
-
32
-
-
0024801278
-
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually
-
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86. (Pubitemid 20026073)
-
(1989)
Journal of the National Cancer Institute
, vol.81
, Issue.24
, pp. 1879-1886
-
-
Gail, M.H.1
Brinton, L.A.2
Byar, D.P.3
Corle, D.K.4
Green, S.B.5
Schairer, C.6
Mulvihill, J.J.7
-
33
-
-
20144365496
-
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
-
DOI 10.1056/NEJMoa050405
-
Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80. (Pubitemid 40365348)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.11
, pp. 1071-1080
-
-
Solomon, S.D.1
McMurray, J.J.V.2
Pfeffer, M.A.3
Wittes, J.4
Fowler, R.5
Finn, P.6
Anderson, W.F.7
Zauber, A.8
Hawk, E.9
Bertagnolli, M.10
-
34
-
-
0034671279
-
SF-36 health survey update
-
Phila Pa 1976
-
Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000;25:3130-9.
-
(2000)
Spine
, vol.25
, pp. 3130-3139
-
-
Ware Jr., J.E.1
-
35
-
-
0030199690
-
A menopause-specific quality of life questionnaire: Development and psychometric properties
-
Erratum, Maturitas 1996;25:231
-
Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-75. [Erratum, Maturitas 1996;25:231.]
-
(1996)
Maturitas
, vol.24
, pp. 161-175
-
-
Hilditch, J.R.1
Lewis, J.2
Peter, A.3
-
37
-
-
12344312699
-
-
version 3.0. March 31
-
Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. March 31, 2003. (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.)
-
(2003)
Common Terminology Criteria for Adverse Events
-
-
-
38
-
-
0037980149
-
Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation
-
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
-
(2003)
Med Care
, vol.41
, pp. 582-592
-
-
Norman, G.R.1
Sloan, J.A.2
Wyrwich, K.W.3
-
39
-
-
0037357355
-
Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: An expert consensus panel report
-
DOI 10.1046/j.1525-1497.2003.20203.x
-
Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003;18:196-202. (Pubitemid 36399456)
-
(2003)
Journal of General Internal Medicine
, vol.18
, Issue.3
, pp. 196-202
-
-
Wyrwich, K.W.1
Fihn, S.D.2
Tierney, W.M.3
Kroenke, K.4
Babu, A.N.5
Wolinsky, F.D.6
-
40
-
-
27244436756
-
Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
-
Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:6931-40.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6931-6940
-
-
Whelan, T.J.1
Goss, P.E.2
Ingle, J.N.3
-
41
-
-
33747058527
-
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17
-
DOI 10.1200/JCO.2005.05.4882
-
Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629-35. (Pubitemid 46630537)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.22
, pp. 3629-3635
-
-
Perez, E.A.1
Josse, R.G.2
Pritchard, K.I.3
Ingle, J.N.4
Martino, S.5
Findlay, B.P.6
Shenkier, T.N.7
Tozer, R.G.8
Palmer, M.J.9
Shepherd, L.E.10
Liu, S.11
Tu, D.12
Goss, P.E.13
-
42
-
-
41949094767
-
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
-
Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-7.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1051-1057
-
-
Eastell, R.1
Adams, J.E.2
Coleman, R.E.3
-
43
-
-
77957708501
-
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study
-
Coleman RE, Banks LM, Girgis SI, et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010;124:153-61.
-
(2010)
Breast Cancer Res Treat
, vol.124
, pp. 153-161
-
-
Coleman, R.E.1
Banks, L.M.2
Girgis, S.I.3
-
44
-
-
33750522464
-
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
-
DOI 10.1016/j.ejca.2006.07.005, PII S0959804906006356
-
Geisler J, Lønning PE, krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006;42:2968-75. (Pubitemid 44667475)
-
(2006)
European Journal of Cancer
, vol.42
, Issue.17
, pp. 2968-2975
-
-
Geisler, J.1
Lonning, P.E.2
Krag, L.E.3
Lokkevik, E.4
Risberg, T.5
Hagen, A.I.6
Schlichting, E.7
Lien, E.A.8
Ofjord, E.S.9
Eide, G.E.10
Polli, A.11
Di, S.E.12
Paolini, J.13
-
45
-
-
79953320008
-
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial
-
Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011;22:857-62.
-
(2011)
Ann Oncol
, vol.22
, pp. 857-862
-
-
Eastell, R.1
Adams, J.2
Clack, G.3
-
46
-
-
78649603622
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-Year analysis of the ATAC trial
-
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-41.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1135-1141
-
-
Cuzick, J.1
Sestak, I.2
Baum, M.3
-
47
-
-
37649008623
-
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial
-
Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007;25:5715-22.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5715-5722
-
-
Mouridsen, H.1
Keshaviah, A.2
Coates, A.S.3
-
48
-
-
33746896140
-
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
-
DOI 10.1007/s10549-006-9207-y
-
Ingle JN, Tu D, Pater JL, et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006;99:295-300. (Pubitemid 44337921)
-
(2006)
Breast Cancer Research and Treatment
, vol.99
, Issue.3
, pp. 295-300
-
-
Ingle, J.N.1
Tu, D.2
Pater, J.L.3
Martino, S.4
Robert, N.J.5
Muss, H.B.6
Piccart, M.J.7
Castiglione, M.8
Shepherd, L.E.9
Pritchard, K.I.10
Livingston, R.B.11
Davidson, N.E.12
Norton, L.13
Perez, E.A.14
Abrams, J.S.15
Cameron, D.A.16
Palmer, M.J.17
Goss, P.E.18
|